Light for Renal Transplant Recipients Having a Sleep-Wake Dysregulation (SleepTx-1)
Primary Purpose
Renal Disease, Sleep Disorders
Status
Completed
Phase
Early Phase 1
Locations
Study Type
Interventional
Intervention
Bright Light Therapy
Wait-list intervention
Sponsored by
About this trial
This is an interventional treatment trial for Renal Disease focused on measuring Sleep quality, Daytime Sleepiness
Eligibility Criteria
Inclusion Criteria:
- For phase 1: all renal transplant recipients transplanted at the University Hospital Basel, Bern and Zurich, speaking German and having an actual address on the follow-up list of the ambulatory center list.
- Renal transplant recipients who have poor Sleep quality and /or daytime sleepiness (phase 1: Cross sectional survey study) and had a Sleep assessment (phase 2: Cross sectional diagnostic interview study)
- Renal transplant recipients who participated in Phase 1 and 2 that were diagnosed with sleep wake dysregulation
- Renal transplant recipients with signed written informed consent.
Exclusion Criteria:
RTx recipients, who participated in phase 2, will be excluded in the study if
- they were diagnosed with sleep disorders as parasomnia, breathing disorders or movement disorders.
- they were diagnosed with alcohol or substance abuse
- they are blind or suffer from a severe vision impairment (cataract), which possibly limits the effect of the light intervention and patients taking photosensitive medications
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Other
Arm Label
Bright Light Therapy
Wait-list intervention
Arm Description
Bright Light Therapy with 10000 lux beginning at day 21 until day 42
Wait-list design Intervention. Bright Light Therapy with 10000 lux beginning at day 63 until day 84, when the 9 study weeks were over.
Outcomes
Primary Outcome Measures
Bedtime
The mean "bedtime" assessed by actimetry of each 3 week period (day 21, 42, 63 ) was used as outcome to be compared with the control group.
Bedtime is expressed in time (hours and minutes)
Secondary Outcome Measures
Full Information
NCT ID
NCT01256983
First Posted
December 8, 2010
Last Updated
January 29, 2014
Sponsor
University of Basel
Collaborators
University Hospital, Basel, Switzerland, Insel Gruppe AG, University Hospital Bern, University Hospital, Zürich
1. Study Identification
Unique Protocol Identification Number
NCT01256983
Brief Title
Light for Renal Transplant Recipients Having a Sleep-Wake Dysregulation
Acronym
SleepTx-1
Official Title
Daily Light Intervention in Renal Transplant Recipients Having a Sleep-Wake Dysregulation
Study Type
Interventional
2. Study Status
Record Verification Date
January 2014
Overall Recruitment Status
Completed
Study Start Date
October 2010 (undefined)
Primary Completion Date
June 2013 (Actual)
Study Completion Date
July 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Basel
Collaborators
University Hospital, Basel, Switzerland, Insel Gruppe AG, University Hospital Bern, University Hospital, Zürich
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Sleep-wake dysregulation is a disturbance in the roughly 24-hour cycle of the circadian rhythm. Well known disorders presenting a sleep-wake dysregulation are seasonal affective disorder, jet lag and shift work. These people experience a serious mood change when the seasons change. When the day-night rhythm is desynchronized, they have sleep disturbances, little energy, and often feel depressed. An established intervention to treat this disorder is bright light therapy. Light therapy is used for affective disorders for shift workers, jet lag symptomatology and for advancing or delaying desynchronized rhythms.Two proxy measures for sleep-wake dysregulation are sleep quality and daytime sleepiness. It is known from cross sectional studies that renal transplant (RTx) recipients have a prevalence between 30% to 62% of poor sleep quality measured by self report; a prevalence of impaired daytime functioning of 34% 12 and a prevalence of depressive symptomatology of 20% to 22%. Sleep-wake dysregulation in other chronically ill population are a risk factor for morbidity and mortality.
RTx nurses in the follow-up care are in the frontline for recipient's symptoms respectively problems. The psychosocial variables that should be addressed, having an association with morbidity and mortality are sleep, daytime functioning, adherence to immunosuppressive medication, exercise, smoking and depressive symptomatology.
In the following research project we will address the following gaps: the fact that nature of sleep disturbances in RTx recipients has never been assessed, that there is no prevalence available on sleep-wake dysregulation and that there is no data on bright light therapy intervention in RTx recipients.
Hypothesis: Renal transplant recipients having a sleep wake disregulation will have an improved sleep quality and less daytime sleepiness after 21 days of light therapy.
Detailed Description
This research project has three phases:
The first phase is a cross sectional survey including all patients transplanted in Basel, Bern and in Zurich speaking German and transplanted at least 6 months ago. Renal transplant recipients having poor sleep quality and / or daytime sleepiness as result of this first phase will be asked to participate in phase two. Phase two is an sleep assessment, resulting in a presumed sleep diagnosis.
Renal transplant recipients having a sleep wake dysregulation, assessed in phase two, will be asked to participate in phase three. Phase three is a pilot randomized controlled trial to compare the sustained impact of bright light therapy on sleep-wake regulation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Renal Disease, Sleep Disorders
Keywords
Sleep quality, Daytime Sleepiness
7. Study Design
Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
30 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Bright Light Therapy
Arm Type
Experimental
Arm Description
Bright Light Therapy with 10000 lux beginning at day 21 until day 42
Arm Title
Wait-list intervention
Arm Type
Other
Arm Description
Wait-list design Intervention. Bright Light Therapy with 10000 lux beginning at day 63 until day 84, when the 9 study weeks were over.
Intervention Type
Behavioral
Intervention Name(s)
Bright Light Therapy
Other Intervention Name(s)
Philips Energy Light
Intervention Description
10000 Lux for 30 Minutes according to sleep wake rhythm
Intervention Type
Behavioral
Intervention Name(s)
Wait-list intervention
Other Intervention Name(s)
Philips Energy Light
Intervention Description
10000 Lux for 30 Minutes according to sleep wake rhythm
Primary Outcome Measure Information:
Title
Bedtime
Description
The mean "bedtime" assessed by actimetry of each 3 week period (day 21, 42, 63 ) was used as outcome to be compared with the control group.
Bedtime is expressed in time (hours and minutes)
Time Frame
Mean Bedtimes over 21 days for each period
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
For phase 1: all renal transplant recipients transplanted at the University Hospital Basel, Bern and Zurich, speaking German and having an actual address on the follow-up list of the ambulatory center list.
Renal transplant recipients who have poor Sleep quality and /or daytime sleepiness (phase 1: Cross sectional survey study) and had a Sleep assessment (phase 2: Cross sectional diagnostic interview study)
Renal transplant recipients who participated in Phase 1 and 2 that were diagnosed with sleep wake dysregulation
Renal transplant recipients with signed written informed consent.
Exclusion Criteria:
RTx recipients, who participated in phase 2, will be excluded in the study if
they were diagnosed with sleep disorders as parasomnia, breathing disorders or movement disorders.
they were diagnosed with alcohol or substance abuse
they are blind or suffer from a severe vision impairment (cataract), which possibly limits the effect of the light intervention and patients taking photosensitive medications
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sabina De De Geest, PhD
Organizational Affiliation
Institute of Nursing Science
Official's Role
Principal Investigator
12. IPD Sharing Statement
Citations:
PubMed Identifier
25182079
Citation
Burkhalter H, Wirz-Justice A, Denhaerynck K, Fehr T, Steiger J, Venzin RM, Cajochen C, Weaver TE, De Geest S. The effect of bright light therapy on sleep and circadian rhythms in renal transplant recipients: a pilot randomized, multicentre wait-list controlled trial. Transpl Int. 2015 Jan;28(1):59-70. doi: 10.1111/tri.12443. Epub 2014 Oct 2.
Results Reference
derived
Learn more about this trial
Light for Renal Transplant Recipients Having a Sleep-Wake Dysregulation
We'll reach out to this number within 24 hrs